{"doi":"10.14789/pjmj.38.56","title":"Intraventricular infusion of nerve growth factor (NGF)","abstract":null,"journal":"Juntendo Medical Journal","year":1992,"id":605993,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1555482,"name":"KOU ETO","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Intraventricular infusion of nerve growth factor (NGF)","abstract":"神経成長因子 (NGF) を成熟ラットの側脳室内に2週間持続投与し, ラットの体重変化に対するNGFの影響を調べた. NGFの濃度による影響を観察するため, 20μg/ml (0.01μg/hr, 総量3.36μg) と100μg/ml (0.05μg/hr, 総量16.8μg) の濃度を変えたNGF投与群を作製した. 投与前後におけるラットの体重を測定したところ, いずれのNGF投与群においても対照群に比べて体重増加が有意に抑制されていた. またNGF20μg/ml投与群と100μg/ml投与群の体重変化の程度に違いは認められなかった. 次にNGF1OOμg/mlを持続投与したラットの体重変化と一日あたりの摂食量を経時的に測定した. 体重変化は投与3日目からすでにNGF群と対照群の値に有意な差を認め, 経時的に両群の体重差が大きくなっていくことが明らかとなった. しかし, NGF投与群と対照群の摂食量に有意な差は認められなかった. 近年NGFが脳内コリン系ニューロンの機能維持に関与することから, アルツハイマー型痴呆 (SDAT) の治療としてNGFの投与が注目されているが, 成熟動物の体重増加をNGFが抑制することは未だ着目されておらず, NGFの全身作用の一つとして今後解析する必要がある.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W2325653985","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.20104261,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://www.jstage.jst.go.jp/article/pjmj/38/1/38_56/_pdf","host_type":"journal"},{"url":"https://www.jstage.jst.go.jp/article/pjmj/38/1/38_56/_pdf","host_type":"publisher"},{"url":"https://doi.org/10.14789/pjmj.38.56","host_type":"journal"}],"fields_of_study":["Cholinesterase and Neurodegenerative Diseases","Nerve injury and regeneration","Cancer Treatment and Pharmacology"],"mesh_terms":[],"keywords":["Nerve growth factor","Endocrinology","Internal medicine","Medicine","Receptor"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T03:40:38.151561Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}